$NNVC’s lead drug, NV-387, targets a $2.5 to $4.3 billion market. It has the potential to treat COVID-19, RSV, influenza, and even monkeypox. NV-387 has successfully completed Phase 1 clinical trials.


Know more: https://tinyurl.com/58b8wyjc